查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679344

肝癌药物市场规模、份额、趋势分析报告：按治疗、类型、分销管道、地区分類的细分趋势，2025-2030 年

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Therapy, By Type, By Distribution Channel, By Region, And Segment Forecasts 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

肝癌药物市场的成长与趋势

根据Grand View Research, Inc.的最新报告，到2030年全球肝癌治疗药物市场规模预计将达到98.1亿美元。

预计 2025 年至 2030 年间，市场复合年增长率将达到 17.9%。肝癌市场的成长主要受到新药供应、强大研发线的存在以及社会意识的提高等因素的推动。肝癌患者数量的增加是由于不健康的生活方式和老年人口的增加。这对于肝癌药物市场是利好。针对对 Nexavar 不耐受的患者开发二线治疗方法预计将对肝癌领域产生重大影响。

肝癌是全球第五大常见癌症，占癌症死亡人数的9.0%。据报道，2012年，全球新诊断的肝癌病例为782,451例，死于肝癌的人数为745,533人。原发性肝癌由于其高度侵袭性和较低的存活率，仍然是一个重大的公共卫生问题。肝细胞癌占原发性肝癌的大多数（75-90％）。肝癌的许多显着原因，包括肝炎感染和肝硬化，都是可以改变的，透过改变生活方式和接种肝炎疫苗等预防策略，有望降低肝癌的发病率和死亡率。

肝癌药物市场报告重点

  • 由于针对与癌细胞生长和扩散相关的特定分子和途径的高精度定位，标靶治疗领域预计将在 2024 年占据最大的市场收益占有率，达到 53.1%。
  • 肝细胞癌 (HCC) 占据肝癌药物市场的主导地位，2024 年的收益占有率为 38.2%。肝细胞癌是最常见的原发性肝癌类型。
  • 到 2024 年，医院药局将以 45.7% 的收益占有率主导肝癌药物市场。
  • 2024年北美肝癌药物市占率为38.7%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肝癌药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析 – 波特五力分析
    • PESTLE分析
    • 管道分析

第四章肝癌药物市场：依治疗类型分類的业务分析

  • 2024 年及 2030 年各疗法市场占有率
  • 治疗细分仪表板
  • 2018 年至 2030 年按治疗类型分類的市场规模、预测和趋势分析
  • 标靶治疗
  • 免疫疗法
  • 化疗
  • 其他的

第五章肝癌药物市场：按类型分類的业务分析

  • 2024 年及 2030 年各类型市场占有率
  • 类型细分仪表板
  • 2018 年至 2030 年按类型分類的市场规模、预测与趋势分析
  • 肝细胞癌
  • 胆管癌
  • 肝母细胞瘤
  • 其他的

第 6 章 肝癌药物市场：依通路分類的业务分析

  • 2024 年和 2030 年按分销管道分類的市场占有率
  • 分销通路细分仪表板
  • 2018 年至 2030 年分销通路市场规模、预测与趋势分析
  • 医院药房
  • 零售药局
  • 网路药局

第 7 章肝癌药物市场：区域、估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区，2018 年至 2030 年
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年各国情况
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 按国家/地区，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Exelixis, Inc.
    • Merck KGaA
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • Thermo Fisher Scientific Inc.
    • Pfizer Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
Product Code: GVR-2-68038-513-7

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is anticipated to reach USD 9.81 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 17.9% from 2025 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The targeted therapy segment held the largest market revenue share of 53.1% in 2024 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 38.2% revenue share in 2024. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.7% in 2024.
  • North America liver cancer drug market held a revenue share of 38.7% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Liver Cancer Drug Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Hepatocellular Carcinoma
    • 5.4.1. Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
  • 5.5. Cholangio Carcinoma
    • 5.5.1. Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
  • 5.6. Hepatoblastoma
    • 5.6.1. Hepatoblastoma Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. UK
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Exelixis, Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck KGaA
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eisai Co., Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol-Myers Squibb Company
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Thermo Fisher Scientific Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Eli Lilly and Company
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Novartis AG
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bayer AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Liver Cancer Drug Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 5 Global Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 10 North America Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 18 Mexico Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 19 Mexico Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 22 Europe Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 25 Germany Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 UK Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 28 UK Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 29 UK Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 31 France Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 France Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 34 Italy Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Italy Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 37 Spain Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Spain Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Denmark Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 40 Denmark Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 Denmark Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Sweden Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 43 Sweden Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Sweden Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Norway Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 46 Norway Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 47 Norway Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 53 Japan Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Japan Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 China Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 56 China Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 China Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 India Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 59 India Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 60 India Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 62 Australia Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 65 South Korea Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 66 South Korea Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 68 Thailand Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 69 Thailand Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 72 Latin America Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 73 Latin America Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 75 Brazil Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 76 Brazil Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 78 Argentina Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 85 South Africa Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 86 South Africa Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 91 UAE Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Liver Cancer Drug Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Therapy and Type Outlook (USD Million)
  • Fig. 10 Distribution Channel Outlook (USD Million)
  • Fig. 11 Competitive Landscape
  • Fig. 12 Liver Cancer Drug Market Dynamics
  • Fig. 13 Liver Cancer Drug Market: Porter's Five Forces Analysis
  • Fig. 14 Liver Cancer Drug Market: PESTLE Analysis
  • Fig. 15 Liver Cancer Drug Market: Therapy Segment Dashboard
  • Fig. 16 Liver Cancer Drug Market: Therapy Market Share Analysis, 2024 & 2030
  • Fig. 17 Targeted Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 19 Chemotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 20 Others Market, 2018 - 2030 (USD Million)
  • Fig. 21 Liver Cancer Drug Market: Type Segment Dashboard
  • Fig. 22 Liver Cancer Drug Market: Type Market Share Analysis, 2024 & 2030
  • Fig. 23 Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
  • Fig. 24 Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
  • Fig. 25 Hepatoblastoma Market, 2018 - 2030 (USD Million)
  • Fig. 26 Others Market, 2018 - 2030 (USD Million)
  • Fig. 27 Liver Cancer Drug Market: Distribution Channel Segment Dashboard
  • Fig. 28 Liver Cancer Drug Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 29 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 30 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 31 Online Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 32 Liver Cancer Drug Market Revenue, By Region
  • Fig. 33 Regional Marketplace: Key Takeaways
  • Fig. 34 Regional Marketplace: Key Takeaways
  • Fig. 35 North America Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Country Dynamics
  • Fig. 37 U.S. Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Country Dynamics
  • Fig. 39 Canada Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico Country Dynamics
  • Fig. 41 Mexico Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany Country Dynamics
  • Fig. 44 Germany Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 45 UK Country Dynamics
  • Fig. 46 UK Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 47 France Country Dynamics
  • Fig. 48 France Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Country Dynamics
  • Fig. 50 Italy Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain Country Dynamics
  • Fig. 52 Spain Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Country Dynamics
  • Fig. 54 Norway Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden Country Dynamics
  • Fig. 56 Sweden Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark Country Dynamics
  • Fig. 58 Denmark Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan Country Dynamics
  • Fig. 61 Japan Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 62 China Country Dynamics
  • Fig. 63 China Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 64 India Country Dynamics
  • Fig. 65 India Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 66 Australia Country Dynamics
  • Fig. 67 Australia Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 68 South Korea Country Dynamics
  • Fig. 69 South Korea Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 70 Thailand Country Dynamics
  • Fig. 71 Thailand Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 73 Brazil Country Dynamics
  • Fig. 74 Brazil Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina Country Dynamics
  • Fig. 76 Argentina Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 77 MEA Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 78 South Africa Country Dynamics
  • Fig. 79 South Africa Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 80 Saudi Arabia Country Dynamics
  • Fig. 81 Saudi Arabia Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 82 UAE Country Dynamics
  • Fig. 83 UAE Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 84 Kuwait Country Dynamics
  • Fig. 85 Kuwait Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 86 Company Categorization
  • Fig. 87 Company Market Position Analysis
  • Fig. 88 Strategic Framework